Please assess the completion status of the following clinical trial:

Trial Title: Cell Therapy in Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients will be eligible if presenting all characteristics described below:~  * ST segment elevation myocardial infarction in two or more contiguous leads, and according to the WHO definition, at least one of the following two:~    i) Presence of chest pain. ii) Elevation of the myonecrosis markers.~ * Age between 30 and 80 years old.~ * Ejection fraction ≤50% on Echocardiogram (Simpson) and segmentary dysfunction of the infarction area, measured between the 3rd and 5th day post AMI.~Among patients submitted to thrombolytic therapy, the angioplasty of the related artery should be preferably done up to 24h after thrombolysis, with a maximum deadline of 72h after thrombolysis.~Exclusion Criteria:~* Patients will be ineligible if presenting any of the characteristics described below:~  * AMI related artery presenting TIMI \< 3 at the moment f cell injection.~ * Left Main Coronary Artery Lesion of \>50% or multivessel coronariopathy (\>70% lesion in vessels with \>2,0mm diameter in left anterior descending, circumflex and right coronary territory) indicating the need for CABG or angioplasty with three or more stents implant.~ * Coronary anatomy, after thrombolytic reperfusion, presenting no need for angioplasty with stent implant.~ * Final Diastolic Pression of the LV higher than 30 mmHg during ventriculography for evaluating EF inclusion criteria for the research protocol (item c of inclusion criteria).~ * Cardiac arrest or Killip IV AMI at admission with need of ventilatory support.~ * Cardiogenic shock persisting up to the third day after AMI (with need of Intra-aortic balloon pump or vasopressors).~ * AMI mechanical complications (ventricular septal defect, papillary muscle rupture, and left ventricular free wall rupture).~ * Significant valve disease, defined as aortic stenosis (mean systolic pressure gradient across the aortic valve \>50mmHg), mitral stenosis with a valvar area less than 1,5 cm,2 moderate to severe aortic and/or mitral regurgitation.~ * Chronic use of immunosuppressive agents.~ * \> 2,0 mg/dl creatinine or previous dialysis treatment.~ * Presence of fever on the past 48h before injection glaring active systemic infection according to ACCP/SCCM (American College of Chest Physicians/Society of Critical Care Medicine) sepsis definition.~ * Sustained ventricular tachycardia 48h after AMI.~ * Illicit drugs abuse or alcohol abuse (based on DSM IV).~ * Any co morbidity, with survival impact in two years.~ * Myocarditis~ * Active liver disease~ * COPD in continuous steroids use.~ * Hematological disease, neoplasm, bone disease or hemostatic disturbances.~ * Inflammatory disease or chronicle infectious disease.~ * Presence of definitive implantation of a cardiac pace maker or cardiac defibrillator.~ * Impossibility to reach a cells suspension of 100 million mononuclear cells due to cells paucity in the bone marrow aspirate.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treated Group (Type: EXPERIMENTAL): Intracoronary injection in the infarcted-related artery of 100 million bone marrow mononuclear cells resuspended in a 10 ml solution of saline with autologous serum.
- Control Group (Type: PLACEBO_COMPARATOR): Intracoronary injection in the infarcted-related artery of placebo solution consisting of a saline containing autologous blood serum.

Based on this trial design, predict the completion outcome and termination type (if applicable).